Showing results (81-90 of 120) with videos related to
Sort By:
Pageof 12
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 1, 2026
Metabolic Response to CDK4/6 Inhibition in ER+ Breast Cancer Creates a Therapeutic Vulnerability in Drug-Tolerant Persister CellsHuijuan Yang, Steven Tau, Andrew D McCray, et al.The Journal of Clinical Investigation|June 10, 2010
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancerTodd W Miller, Bryan T Hennessy, Ana M González-Angulo, et al.Plos One|November 2, 2018
Correction: Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.Plos One|June 7, 2018
Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulationArlene I Ramsingh, Steven J Gray, Andrew Reilly, et al.Research Square|April 8, 2024
ENGINEERED NANOBODIES WITH PROGRAMMABLE TARGET ANTIGEN PROTEOLYSIS (PTAP) FUSIONS REGULATE INTRACELLULAR ALPHA-SYNUCLEIN IN VITRO AND IN VIVODiptaman Chatterjee, Lianna Y D'Brant, Benjamin M Hiller, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 31, 2018
Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER<sup>+</sup> breast cancerKevin Shee, Amanda Jiang, Frederick S Varn, et al.Cancer Biomarkers : Section a of Disease Markers|July 6, 2020
Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancerKevin Shee, John D Seigne, Margaret R Karagas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Biomarkers of response to Akt inhibitor MK-2206 in breast cancerTakafumi Sangai, Argun Akcakanat, Huiqin Chen, et al.Cancer Research|July 22, 2011
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancerXuemei Yang, Alexa B Turke, Jie Qi, et al.Journal of Neuro-Oncology|August 11, 2019
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastomaTodd W Miller, Nicole A Traphagen, Jing Li, et al.Pageof 12